Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.
about
Antibody-drug conjugates as novel anti-cancer chemotherapeuticsEvolving concepts in cancer therapy through targeting sphingolipid metabolismAcute Pancreatitis-Progress and Challenges: A Report on an International SymposiumThe birth of chemotherapy at Yale. Bicentennial lecture series: Surgery Grand RoundA brief history of cancer: age-old milestones underlying our current knowledge database.Sulfur, oxygen, and nitrogen mustards: stability and reactivity.Targeting DNA Mismatches with Rhodium Metalloinsertors.Evolution of acquired resistance to anti-cancer therapy.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Update from Asia. Asian studies on cancer chemoprevention.Historical review of lymphomas.Historical review of Hodgkin's disease.Toward hypoxia-selective DNA-alkylating agents built by grafting nitrogen mustards onto the bioreductively activated, hypoxia-selective DNA-oxidizing agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (tirapazamine).Using synthetic DNA interstrand crosslinks to elucidate repair pathways and identify new therapeutic targets for cancer chemotherapy.Leukaemia - a brief historical review from ancient times to 1950.A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphomaThe chemotherapy of Hodgkin's disease: past experiences and future directions.History of pediatric oncology.O. Harold Warwick: Canada's first medical oncologist.The role of radiotherapy in Hodgkin's lymphoma: what has been achieved during the last 50 years?Role of lipegfilgrastim in the management of chemotherapy-induced neutropeniaThe role of funding and policies on innovation in cancer drug development.Cancer pharmacotherapy: 21st century 'magic bullets' and changing paradigms.Local iontophoretic administration of cytotoxic therapies to solid tumorsPrecision renal medicine: a roadmap towards targeted kidney fibrosis therapies.Molecular chess? Hallmarks of anti-cancer drug resistanceIdentifying radiation-induced survivorship syndromes affecting bowel health in a cohort of gynecological cancer survivorsPoint/counterpoint: early-stage Hodgkin lymphoma and the role of radiation therapy.Incorporation of metabolic activation potentiates cyclophosphamide-induced DNA damage response in isogenic DT40 mutant cellsDNA interstrand crosslink repair and cancer.Cancer nanomedicines: so many papers and so few drugs!Changes in the management and survival rates of patients with oral cancer: a 30-year single-institution studyThe contribution of Gianni Bonadonna to the history of chemotherapy.Resistance to chemotherapy: new treatments and novel insights into an old problem.Topical chemotherapy in cutaneous T-cell lymphoma: positive results of a randomized, controlled, multicenter trial testing the efficacy and safety of a novel mechlorethamine, 0.02%, gel in mycosis fungoides.ATR-101 disrupts mitochondrial functions in adrenocortical carcinoma cells and in vivo.Is it time for a new paradigm for systemic cancer treatment? Lessons from a century of cancer chemotherapyDNA crosslinking damage and cancer - a tale of friend and foe.Assessment of the evolution of cancer treatment therapiesMode of action and biosynthesis of the azabicycle-containing natural products azinomycin and ficellomycin.
P2860
Q26800175-15C8FECE-1F96-44DD-9080-76A7BB3D5C80Q26863646-40636292-CD99-4D59-87D4-36BBAE9A3919Q27314738-AF422A9A-C0E0-474F-96E4-33C71AE34855Q28241501-744548DE-77FC-499A-A06F-ABA264770F64Q30365586-0DA7FAFD-66A2-4FD7-B1F1-4021D8AA3C1CQ30573557-2A0A41E7-FA5A-4802-B920-03DAE3C679F6Q31136996-1DB4D90E-D0DF-4527-A137-C28798FE01F0Q33758382-140F5580-9801-4434-8AFD-8194C271112FQ33798999-5789B56E-264C-44CA-B0D9-6B539222B151Q33834345-90B40B05-1AA6-4D50-8CF0-60BB0A8F8244Q33962044-24242C69-7950-4B4D-BBD3-8D7827E0BD5CQ34039931-C635ED51-E57A-44ED-8DC5-E186C7E4BF73Q34061361-0F503ABA-3E72-4F89-8DA8-22FA7421831EQ34132691-25DAE1A3-A9B6-439B-BA4E-559A4929BD20Q34135337-A6A5CFDA-B6A4-4C84-AD2E-B193128BD490Q34479660-A5C184BB-A828-45B6-B6B4-B89E52C3AF80Q34690701-417B929F-3945-46CE-A1D2-C81D2C7284F5Q34797422-54ABA806-E40A-400F-A33C-9FFD9D4864DFQ35027015-91541B23-EE7F-435D-AEEA-FB6E217FF6B3Q35091669-CDE1B290-4A3C-4F04-B8F6-14D040856BC1Q35298321-643F91D8-BFE5-49A4-81AF-C96AFE7F0766Q35602147-8BBB2619-D684-43FB-A3BD-4215C22755EEQ35827640-DA8BB4B9-BC1E-4FA6-8F8E-2380CE411891Q35983594-1A812215-DB7F-4151-A047-8E273F49F6F5Q36015077-40047991-4E05-4087-B355-207C706A6A96Q36240941-76FE3528-B082-48DD-9706-B7704E697B3CQ36270141-B5C05FE3-BD94-46A7-A501-AFD0538EFBE7Q36440046-F5DA67CB-219A-4A2B-9833-9E75516011E7Q36492435-8811776E-0B60-4D36-91A7-F0A2B26DC417Q36576047-6698FE52-42B8-407A-BF11-860C16DAB893Q36589023-659A3E9C-050A-4C8B-9462-ADF886BAE70BQ36601266-C4714963-5FD5-44E5-A07D-E72611E412CBQ36704828-0296A3F4-1BC9-4BA0-A5AA-9799D0BC43D1Q36858079-57C49276-A44E-412C-9BD8-B5FD5457A177Q36870654-1FDE2EDE-5189-44E2-A326-BD012F3677FFQ36951577-A13FDA99-3BB7-45B3-850F-A8BEC18883F5Q36952188-DF9DFCA4-180F-4B82-A05E-B71C0C40A920Q37127343-8123BC76-0D3F-41FC-8D63-DAF534770CF7Q37137408-8D557D50-1CAC-4843-A11F-EF2090A59AEDQ37843695-F3537E34-4AA8-43A9-BD0C-485AE6F057F4
P2860
Nitrogen mustard therapy; use of methyl-bis (beta-chloroethyl) amine hydrochloride and tris (beta-chloroethyl) amine hydrochloride for Hodgkin's disease, lymphosarcoma, leukemia and certain allied and miscellaneous disorders.
description
1946 nî lūn-bûn
@nan
1946 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
1946 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
1946年の論文
@ja
1946年論文
@yue
1946年論文
@zh-hant
1946年論文
@zh-hk
1946年論文
@zh-mo
1946年論文
@zh-tw
1946年论文
@wuu
name
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@ast
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@en
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@nl
type
label
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@ast
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@en
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@nl
prefLabel
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@ast
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@en
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@nl
P1476
Nitrogen mustard therapy; use ...... d and miscellaneous disorders.
@en
P2093
L S GOODMAN
M M WINTROBE
P304
P356
10.1001/JAMA.1946.02870380008004
P577
1946-09-01T00:00:00Z